RNS Number : 1901T
Quantum Exponential Group PLC
23 November 2021
23 November 2021
Quantum Exponential Group PLC ('the Company' or 'Quantum Exponential')
Investor presentation
Quantum Exponential Group PLC, a company formed to identify investment opportunities in the quantum technology sector and admitted to trading on the AQSE Growth Market Access Segment, is pleased to announce that Martin Schwedler, Chief Executive Officer, and Stuart Nicol, Chief Investment Officer, will provide a live investor presentation on Tuesday, 2 December 2021 at 12:00pm GMT London via the 'Investor Meet Company' platform.
The webinar is open to all existing and potential investors and will consist of a presentation, followed by a Q&A session. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Quantum Exponential via:
https://www.investormeetcompany.com/quantum-exponential-group-plc/register-investor
**ENDS**
For further information please visit
www.quantumexp.co.uk
or contact:
Martin Schwedler, Chief Executive Officer
c/o +44 (0)207 236 1177
Novum Securities (AQSE Corporate Adviser)
David Coffman / Lucy Bowden
Tel: +44 (0)20 7399 9400
Oberon Capital (Broker)
Tel: +44 (0)20 3179 5344
Mike Seabrook, Chris Crawford, Robert Hayward
St Brides Partners Limited (Financial PR)
Catherine Leftley / Isabelle Morris Tel: +44 (0)207 236 1177
About Quantum Exponential Group Plc
Quantum Exponential is a first of its kind, AQSE Growth Market SPAC, focused on opportunities in quantum technology and the wider quantum computing sector, with an advisory board made up of industry advisors, entrepreneurs, and technology investment professionals with broad access to quantum opportunities and markets. Quantum Exponential's investment strategy is to assemble a portfolio of minority investments in early-stage global quantum technology companies, primarily in NATO allied countries, offering institutional and private investors access to revolutionising technologies and industries in the realms of artificial intelligence, manufacturing and healthcare.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
NEXUUSWRANUAUAA